As a result, it is likely that this polymorphism interacts pathogenetically with other comorbidities (such as diabetes and hypertension) and other genotypes, and that bardoxolone methyl may be acting on related factors other than NRF2 [22]. This evidence concerns the gene NFE2L2 and Hypertension.